Even if Medicaid expansion survives, states will likely seek waivers on enrollment

At the core of both the House and Senate Republicans’ proposals to replace the Affordable Care Act (ACA) is rolling back the law’s expansion of Medicaid. Whether or not the expanded eligibility stays in place, enrollment rules are likely to be changed by states, with encouragement from HHS and CMS.

NPR and ProPublica report these changes will involve beneficiaries having to verify their eligibility more frequently. Other proposed changes have included work requirements for “able-bodied” adults on Medicaid, drug testing and setting on caps on the number of enrollees and how long they can be covered by the program.

“All of the bells and whistles and hoops that people have to jump through create an enormous amount of red tape and that depresses enrollment,” said Joan Alker, executive director of the Center for Children and Families, a research center at Georgetown University. “That’s a proven strategy.”

Supporters of the changes say it would help clear programs of ineligible enrollees, like enrollees who had died years earlier or moved out of state but were still included on rolls. The checks don’t have to be intrusive, said Josh Archambault, senior fellow at the conservative-leaning Foundation for Government Accountability.

“If somebody gets a job, that’s great. They may no longer be able to qualify for the program,” he said. “If they still qualify, they can sign right back up.”

Read the full article at the link below:

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.